Table 1. Demographics and biomarker concentrations for all AD patients, MCI patients and controls.

Study	Diagnosis	Nr	Sex (M/F)	Age (years)	Aβ1–42 (pg/ml)	P-tau181(pg/ml)	T-tau (pg/ml)	MMSE	Aβo (fg/ml)
I	Control	31	16/15	61 (52, 67)	690 (466, 898)	47 (33, 61)	285 (188, 365)	29 (28, 29)	522 (339, 781)
	AD	42	10/32	79 (74, 81)***	370 (318, 415)***	92 (80, 116)***	770 (640, 895)***	21 (19, 23)***	1040 (773, 1,303)***
II	Control	22	10/12	69 (66, 72)	780 (645, 1,060)	–	405 (178, 500)	30 (30, 30)	0 (0, 0)
	AD	51	22/29	79 (75, 81)***	440 (326, 508)***	–	623 (465, 858)***	23 (20, 26)***	717 (0, 1,490)***
III	Control	62	17/45	74(68, 78)	298 (237, 342)	33 (23, 41)	79 (56, 97)	29 (28, 30)	0 (0, 0)
	MCI-AD	58	21/37	78(73, 81)	146 (119, 177)***	49 (36, 67)***	129 (93, 181)**	26 (25, 27)***	0 (0, 313)**
	MCI-Stable	77	34/43	67(62, 75)***	266(217, 298)**	27(19, 36)*	71 (50, 90)	28 (28, 29)**	0 (0, 295)
IV	Control	33	13/20	69 (62, 72)	867 (737, 1060)	–	383 (250, 502)	30 (30, 30)	1538 (504, 2408)
	Severe	11	7/4	79 (68, 82)**	398 (366, 400)***	–	937 (648, 1270)***	12 (13, 16)***	1250 (576, 2082)
	Moderate	51	21/30	80 (75, 83)***	435 (370, 494)***	–	760 (595, 886)***	21 (20, 23)***	2647 (1395, 3451)***
	Mild	44	18/26	77 (74, 81)***	473 (440, 524)***	–	848 (631, 899)***	27 (26, 28)***	2467 (1250, 3387)**

Data are given as medians with 25th and 75th percentiles.

^* p<0.05,

^** p<0.01,

^*** p<0.001 vs. control group.

The analyses of Aβ_1–42, P-tau₁₈₁ and T-tau have been performed with ELISA earlier [22], [48], [49], [50].